Keith Stewart, MD from Mayo Clinic Division of Hematology and Oncology discusses the analysis from the randomized phase 3 Aspire trial and Carfilzomib, Lenalidomide, & Dexamethasone V. Lenalidomide & Dexamethasone at the 2017 American Society of Hematology.
Analysis from the Randomized Phase 3 Aspire Trial – Carfilzomib, Lenalidomide, & Dexamethasone V. Lenalidomide & Dexamethasone
